The FDA cleared bemotrizinol on Tuesday, ending a two-decade drought of new over-the-counter sunscreen ingredients. This compound, common in Asian and European markets, blocks both UVA and UVB rays. The move follows a request from DSM Nutritional Products LLC to add the ingredient to the list of safe and effective options.

U.S. regulations treat sunscreens as drugs rather than cosmetics, which makes the authorization process expensive and slow for manufacturers. Bemotrizinol offers a competitive edge because its large molecule size prevents absorption into the bloodstream. This removes safety uncertainty found in other compounds and provides a more stable formula that lasts longer under direct sun.

Consumers will likely see a shift in product texture as companies move away from chalky mineral films. International brands can now import existing formulas into the U.S. market more easily. This change addresses a specific market need for cosmetically elegant products that do not leave a white cast on the skin.

Industry leaders now have a tool that is better for sensitive skin and less irritating than current options. While existing products remain effective, this approval allows American companies to compete with international standards. The agency's decision simplifies the path for manufacturers to launch high-performance, non-absorbent sunscreens.